Immune check point inhibitors
Showing 1 - 25 of >10,000
Adverse Events in Patients Treated With Immune Check Point
Recruiting
- Immune-related Adverse Event
- Antiinflammatory/DMARDs
-
Kristiansand, Norway
- +4 more
Sep 15, 2022
Advanced Solid Tumor, Stereotactic Body Radiotherapy, Immune Checkpoint Inhibitor Trial in Peking (Cadonilimab, Stereotactic
Not yet recruiting
- Advanced Solid Tumor
- +4 more
- Cadonilimab
- Stereotactic body radiotherapy
-
Peking, Beijing, ChinaDepartment of radiation oncology, Peking University Third Hospit
Jun 20, 2023
Physical Activity and Exercise in Cancer Immunotherapy Treatment
Not yet recruiting
- Cancer
- Physical Activity and Exercise in Cancer Immunotherapy Treatment - Exploratory study of experiences and perceptions
- (no location specified)
Nov 22, 2023
The Status of Immune Checkpoints at Gastrointestinal Cancer
Completed
- Gastrointestinal Cancer
- Flow cytometric analysis
-
Istanbul, TurkeyIstanbul Training and Reseach Hospital
Dec 4, 2022
Acral Melanoma, Mucosal Melanoma Trial in Seoul (Pembrolizumab, Vactosertib)
Not yet recruiting
- Acral Melanoma
- Mucosal Melanoma
- Pembrolizumab, Vactosertib
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Jun 23, 2022
Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France
Not yet recruiting
- Metastatic Renal Cell Carcinoma
- Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
- Combination PD-1/PD-L1 ICI + VEGFR-TKI
- Treatment pause
-
Bayonne, France
- +24 more
Aug 10, 2022
Locally Advanced Head Neck Cancer Trial in Kuwait (Pembrolizumab)
Recruiting
- Locally Advanced Head and Neck Cancer
-
Kuwait, KuwaitKuwait Cancer Control Center
Apr 13, 2021
Squamous Cell Head and Neck Carcinoma Trial (Durvalumab, radiotherapy, Placebo)
Withdrawn
- Squamous Cell Head and Neck Carcinoma
- Durvalumab
- +3 more
- (no location specified)
May 6, 2021
Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer Trial in Sutton (ASTX660, Pembrolizumab)
Recruiting
- Advanced Cancer
- +2 more
-
Sutton, United KingdomRoyal Marden NHS Foundation Trust
May 25, 2022
Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis Trial in Weston (anonymized data
Recruiting
- Breast Cancer
- +4 more
- anonymized data collection during programmed surveillance clinical follow up
-
Weston, FloridaCleveland Clinic Florida
Oct 27, 2022
Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma Trial in Worldwide (EO2401)
Recruiting
- Adrenocortical Carcinoma
- +2 more
- EO2401
-
Houston, Texas
- +9 more
Dec 7, 2021
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In
Recruiting
- Lung Cancer
- +2 more
- Standard of care immune checkpoint inhbitors
-
Fairway, Kansas
- +1 more
Sep 19, 2022
Immune Checkpoint Inhibitors Nephrotoxicity
Recruiting
- Kidney Injury
- Antineoplastics Toxicity
- Early kidney damage biomarkers
- Predisposition to kidney injury biomarkers
-
Salamanca, Spain
- +1 more
Jul 26, 2022
Locally Advanced/Metastatic Solid Tumors Trial in Newport Beach, San Diego, Canton (FL115)
Active, not recruiting
- Locally Advanced/Metastatic Solid Tumors
-
Newport Beach, California
- +2 more
Nov 10, 2023
Immune-Mediated Colitis Trial in Herlev (Vedolizumab, Prednisolone)
Recruiting
- Immune-Mediated Colitis
-
Herlev, DenmarkHerlev University Hospital
Aug 16, 2022
Primary and Metastatic Tumors in Renal Cell Carcinoma and
Recruiting
- Renal Cell Carcinoma
- +4 more
- Immune checkpoint inhibitor targeting PD1
-
Philadelphia, PennsylvaniaFox Chase Cancer Center - Philadelphia
Jan 27, 2023
Breast Cancer, Colon Cancer, Lung Cancer Trial in Tucson (Automated Telephone Symptom Management (ATMS) and Telephone
Not yet recruiting
- Breast Cancer
- +4 more
- Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C)
- Active control comparator
-
Tucson, ArizonaUniversity of Arizona Cancer Center
Feb 6, 2023
Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma Trial in Jerusalem
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Pembrolizumab
-
Jerusalem, IsraelSharett institute, Hadassah University Hospital - Ein-Kerem
Nov 8, 2021
Multiple Myeloma, Lymphoma Trial in Washington, Hackensack (Ipilimumab, Nivolumab)
Active, not recruiting
- Multiple Myeloma
- Lymphoma
-
Washington, District of Columbia
- +1 more
Dec 2, 2021
2D and 3D Primary Cell Cultures From Gastric and
Not yet recruiting
- Gastric and Gastroesophageal Junction Cancer
-
Berlin, GermanyDepartment of Anesthesiology and Operative Intensive Care Medici
Sep 13, 2022
Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)
Not yet recruiting
- Gastric
- Colorectal Adenocarcinoma
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Nov 1, 2023
Pathways to Mitigate Immune-Related Adverse Events With Cancer
Recruiting
- Cancer
- systemic corticosteroid or biologic
-
Denver, Colorado
- +1 more
Sep 8, 2021
Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)
Recruiting
- Cholangiocarcinoma
- Novel combination of chemotherapy and immunotherapy
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jul 28, 2022
NSCLC Trial in Shanghai (Pembrolizumab, Lenvatinib)
Recruiting
- NSCLC
-
Shanghai, ChinaDepartment of Oncology, Shanghai Lung Cancer Center, Shanghai Ch
Dec 7, 2021
Advanced Malignant Solid Tumor Trial in Sacramento (CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc,
Terminated
- Advanced Malignant Solid Neoplasm
- CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
- Placebo Administration
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Mar 8, 2022